CCTV News: According to the WeChat WeChat official account of Shishuo Xinyu, the State Administration for Market Regulation recently approved the issuance of six national first-level standard substances, including CDKN2A/RARβ2/RASSF1A/SHOX2 gene promoter regional methylation (5’-methylcytosine) plasmid DNA, EGFR gene mutation (19DEL) genomic DNA. This series of standard substances is independently developed, filling the gap in my country's standard substances in the field of molecular tumor diagnosis, effectively improving the accuracy and comparability of genetic testing results, helping to detect and diagnose cancer early, and providing reliable technical support for patients to formulate individualized drug plans, and ensuring people's lives and health.
The newly approved and released methylated plasmid DNA standard substance provides a reliable basis for traceability of liquid biopsy technology, improving the accuracy of early methylation screening for diseases such as lung cancer and blood tumors. The newly approved EGFR gene mutation genomic DNA standard substance can significantly improve the quality of accompanying diagnosis of targeted treatment of non-small cell lung cancer, promote the precise use of targeted drugs, and effectively improve the effectiveness of lung cancer treatment.
